Why stool testing matters
Blood tests tell you about the systemic environment — what's circulating, what inflammatory markers are elevated, what nutrients are depleted. They don't tell you what's happening inside the gut itself.
The gut is not passive plumbing. It houses approximately 70% of the immune system, produces roughly 90% of the body's serotonin, communicates bidirectionally with the brain via the vagus nerve, and contains a microbial ecosystem of around 38 trillion organisms whose collective metabolic output influences everything from mood and cognition to hormone clearance and immune regulation.
When the gut environment is dysregulated — whether through pathogen overgrowth, barrier dysfunction, enzyme insufficiency, or microbiome imbalance — the effects are felt system-wide. But those effects often don't show up on a standard blood panel. They show up as symptoms that get labelled IBS, unexplained fatigue, hormonal chaos, or anxiety, and treated accordingly.
The GI-MAP (Gastrointestinal Microbial Assay Plus) uses quantitative polymerase chain reaction (qPCR) technology to identify and quantify the DNA of specific organisms — pathogens, commensal bacteria, opportunistic organisms, fungi, parasites, and viruses — from a single stool sample. It also measures markers of gut barrier integrity, immune function, and digestive efficiency. Here are five of the most clinically significant things it reveals.
H. pylori is present in approximately 44% of the global population. Many carriers have no obvious digestive symptoms. But H. pylori chronically impairs stomach acid production, which disrupts protein digestion, iron absorption, and B12 absorption downstream. It produces ammonia as a metabolic byproduct, which alkalises the stomach environment and creates conditions for bacterial overgrowth further along the gastrointestinal tract.
The clinical presentation is frequently fatigue, low ferritin, B12 insufficiency, and digestive discomfort that is vague and intermittent rather than acute. A blood test doesn't detect it. A standard NHS stool culture is not sensitive enough to reliably identify it. The GI-MAP's qPCR technology quantifies H. pylori and identifies which virulence factors are present — information that determines how aggressively the infection needs to be addressed.
Other pathogens the GI-MAP identifies that standard testing routinely misses include Blastocystis hominis, Dientamoeba fragilis, Cryptosporidium, and Giardia — all associated with chronic digestive symptoms, fatigue, and immune disruption that get labelled as functional disorders when no pathogen is found by conventional methods.
Intestinal permeability — the condition colloquially known as leaky gut — is real, measurable, and clinically significant. It refers to the breakdown of the tight junction proteins that normally regulate what passes from the gut lumen into the bloodstream. When these junctions are compromised, partially digested food particles, bacterial endotoxins, and microbial metabolites enter systemic circulation and drive a chronic low-grade inflammatory response.
The GI-MAP measures two specific markers of gut barrier integrity: Zonulin and Occludin/Zonulin antibodies. Zonulin is a protein that regulates tight junction permeability. Elevated Zonulin indicates active gut barrier dysfunction. Antibodies to Occludin and Zonulin indicate that the immune system has mounted a response to these proteins — a marker of more established or chronic barrier damage.
This is information that no blood test provides. Elevated hs-CRP on a blood panel tells you there's systemic inflammation. The GI-MAP tells you whether a compromised gut barrier is the source of it.
The GI-MAP measures Elastase-1, an enzyme produced by the pancreas that is excreted unchanged in stool. Low Elastase-1 is a reliable marker of exocrine pancreatic insufficiency — the pancreas not producing adequate digestive enzymes to properly break down fats, proteins, and carbohydrates.
This matters because inadequately digested food arriving in the colon becomes a substrate for fermentation by gut bacteria, producing gas, bloating, and inflammatory compounds. It also means that even an excellent diet provides suboptimal nutritional return — nutrients that are consumed but not effectively absorbed.
The test also measures Steatocrit, a marker of fat malabsorption, and provides information on beta-glucuronidase activity — an enzyme produced by certain gut bacteria that can reactivate oestrogens in the gut, relevant to hormonal health and particularly to oestrogen dominance presentations.
Secretory IgA (sIgA) is the primary antibody of gut mucosal immunity. It's the first line of immune defence in the gut — coating pathogens and preventing them from adhering to the gut wall. The GI-MAP measures sIgA directly.
Low sIgA indicates a depleted gut immune system — often seen after chronic stress, prolonged antibiotic use, or gut infection. A person with low sIgA is immunologically vulnerable in the gut: pathogens establish more easily, dysbiosis persists longer, and the inflammatory burden accumulates more readily.
Elevated sIgA indicates active immune challenge — the gut immune system is working hard against something. This finding, combined with pathogen data, points toward specific clinical priorities. Neither pattern shows up on a standard blood panel with any specificity.
Oxalates are naturally occurring compounds found in many foods — spinach, almonds, beetroot, sweet potato, chocolate. In a healthy gut, oxalate-metabolising bacteria (particularly Oxalobacter formigenes) break down dietary oxalates before they can be absorbed.
When these bacteria are depleted — through antibiotic use, dysbiosis, or other disruption — oxalate absorption increases significantly. Elevated oxalates contribute to kidney stone formation, joint pain, urinary symptoms, thyroid disruption, and a broad inflammatory burden. The connection between dietary oxalates and persistent fatigue, joint pain, or systemic inflammation is not something that standard blood chemistry reveals.
The GI-MAP identifies oxalate-metabolising bacteria as part of the commensal bacteria section. Combined with the Organic Acids Test (OAT), which measures urinary oxalates directly, this cross-reference provides a complete picture of oxalate burden and its likely clinical contribution. This is the kind of cross-test pattern matching that makes the five-test approach genuinely different from any single investigation.
What the GI-MAP doesn't tell you
It's worth being honest about this. The GI-MAP is a snapshot of the gut environment at a single point in time. It identifies what's present and in what quantities. It doesn't tell you definitively why — that requires clinical context, intake data, and cross-referencing with other tests.
Finding H. pylori on a GI-MAP doesn't automatically mean it's causing all the symptoms. Finding elevated Candida doesn't mean aggressive antifungal treatment is the next step. Finding low Akkermansia (a beneficial commensal associated with gut barrier integrity) is a finding, not a prescription.
The interpretation matters as much as the data. A stool test result without clinical context is a list of numbers. In the context of a full intake history, symptom questionnaire, lifestyle assessment, and the rest of the five-test panel, it becomes part of a clinical picture.
The most common mistake I see is clients who have had a GI-MAP through another practitioner and received a protocol that addresses the findings in isolation — kill H. pylori, add these probiotics, take these enzymes. Six months later they feel marginally better but not resolved, because the dysbiosis was driven by factors the protocol didn't address: low stomach acid, poor motility, chronic stress, food sensitivity burden, or HPA axis dysregulation running in the background.
The gut doesn't exist in isolation from the rest of the body. Neither does its testing.
Who should consider GI-MAP testing?
In the TDG five-test programme, the GI-MAP is one of five simultaneous tests — run alongside blood chemistry, DUTCH Plus hormone panel, organic acids, and food sensitivity. The cross-referencing between these tests is where the most clinically significant patterns emerge.
But as a standalone starting point, GI-MAP testing is particularly relevant for anyone with:
Persistent digestive symptoms — bloating, gas, unpredictable bowel habits, reflux, or pain that hasn't been explained by standard investigations.
Chronic fatigue with no clear cause — particularly when the fatigue is associated with digestive symptoms, even mild ones. The gut-energy connection is underappreciated.
Hormonal symptoms that haven't responded to hormone-focused treatment — particularly oestrogen dominance presentations, where beta-glucuronidase activity in the gut is a relevant driver.
Immune vulnerability — frequent infections, slow recovery, or a sense of chronically depleted resilience.
Skin conditions — acne, eczema, psoriasis, and rosacea all have documented gut connections that warrant investigation before or alongside topical treatment.
The bottom line
Standard blood panels are designed to diagnose disease. The GI-MAP is designed to investigate function. These are genuinely different aims and they require genuinely different tools.
If you've been told your blood tests are normal, you've been prescribed probiotics that haven't worked, or you've been managing IBS with dietary restriction without ever understanding what's actually driving it — a DNA-based stool analysis is the investigation that closes those gaps.
Most people with chronic gut symptoms have never had one. That's not because they don't need it. It's because their GP's testing toolkit doesn't include it.